S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
Log in
OTCMKTS:INVVY

Indivior Stock Forecast, Price & News

$9.16
+0.01 (+0.11 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.96
Now: $9.16
$9.20
50-Day Range
$6.55
MA: $7.22
$8.92
52-Week Range
$2.23
Now: $9.16
$40.00
Volume11,057 shs
Average Volume13,588 shs
Market Capitalization$1.34 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.3
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's products focuses on treating substance use disorder, opioid use disorder, and schizophrenia. It offers SUBLOCADE injection for subcutaneous use; SUBOXONE sublingual film; and PERSERIS for extended-release injectable suspension, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Indivior logo

MarketRank

Overall MarketRank

0.76 out of 5 stars

Medical Sector

1142nd out of 1,926 stocks

Pharmaceutical Preparations Industry

526th out of 773 stocks

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:INVVY
Previous SymbolNASDAQ:INVVY
CUSIPN/A
CIKN/A
Phone804-379-1090
Employees796

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$785 million
Cash Flow$1.83 per share
Book Value$1.43 per share

Profitability

Net Income$134 million

Miscellaneous

Market Cap$1.34 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableNot Optionable
$9.16
+0.01 (+0.11 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INVVY News and Ratings via Email

Sign-up to receive the latest news and ratings for INVVY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Indivior (OTCMKTS:INVVY) Frequently Asked Questions

How has Indivior's stock been impacted by Coronavirus (COVID-19)?

Indivior's stock was trading at $2.84 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INVVY stock has increased by 222.5% and is now trading at $9.16.
View which stocks have been most impacted by COVID-19
.

Is Indivior a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Indivior stock.
View analyst ratings for Indivior
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Indivior?

Wall Street analysts have given Indivior a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Indivior wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Indivior's next earnings date?

Indivior is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Indivior
.

What guidance has Indivior issued on next quarter's earnings?

Indivior updated its FY 2020 Pre-Market earnings guidance on Thursday, October, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $595-620 million.

Are investors shorting Indivior?

Indivior saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,000 shares, an increase of 900.0% from the December 15th total of 100 shares. Based on an average daily trading volume, of 17,700 shares, the short-interest ratio is currently 0.1 days.
View Indivior's Short Interest
.

Who are some of Indivior's key competitors?

Who are Indivior's key executives?

Indivior's management team includes the following people:
  • Mr. Mark Crossley, CEO & Exec. Director
  • Mr. Ryan Preblick, CFO & Exec. Director
  • Dr. Christian Heidbreder, Chief Scientific Officer
  • Mr. Jason Thompson, VP of Investor Relations
  • Ms. Cynthia Cetani, Chief Integrity & Compliance Officer
  • Mr. Jon Fogle, Chief HR Officer
  • Mr. Richard Simkin, Chief Commercial & Strategy Officer
  • Ms. Sue Learned, Sr. VP of Global Clinical Devel.
  • Hillel West, Chief Manufacturing & Supply Officer
  • Ms. Kathryn Hudson, Company Sec.

What is Indivior's stock symbol?

Indivior trades on the OTCMKTS under the ticker symbol "INVVY."

How do I buy shares of Indivior?

Shares of INVVY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Indivior's stock price today?

One share of INVVY stock can currently be purchased for approximately $9.16.

How big of a company is Indivior?

Indivior has a market capitalization of $1.34 billion and generates $785 million in revenue each year. The company earns $134 million in net income (profit) each year or $1.15 on an earnings per share basis. Indivior employs 796 workers across the globe.

What is Indivior's official website?

The official website for Indivior is www.indivior.com.

How can I contact Indivior?

Indivior's mailing address is 10710 Midlothian Turnpike, North Chesterfield VA, 23235. The company can be reached via phone at 804-379-1090 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.